31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma

✍ Scribed by F. Süllentrop; D. Moka; S. Neubauer; G. Haupt; U. Engelmann; J. Hahn; H. Schicha

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 159 KB
• Volume: 15
• Category: Article
• ISSN: 0952-3480
• DOI: 10.1002/nbm.758

✦ Synopsis

Abstract

Advanced renal cell carcinoma (RCC) has a poor prognosis and is characterized by an unpredictable clinical course. The aim of this study was to assess the systemic phospholipid distribution as a possible marker of tumor stage and tumor spread beyond the kidney. To this end, the effect of renal cell carcinoma (RCC) on phospholipid concentrations in blood plasma using ^31^P NMR spectroscopy was studied in: (a) 29 patients with RCC prior to nephrectomy; (b) 19 healthy volunteers; (c) three patients with other renal tumors (renal metastases of bronchial carcinoma and of renal pelvic carcinoma, and a benign renal tumor). Furthermore, the phospholipid concentrations of eight patients of group (a) were determined 6 months after nephrectomy, when they were in remission. We found considerable deviations in the concentrations of the lysophosphatidylcholines (LPC1, LPC2) in both male and female patients with RCC compared to healthy volunteers (male—LPC1 0.217 ± 0.062 vs 0.297 ± 0.049 mmol/l, LPC2 0.036 ± 0.014 vs 0.068 ± 0.024 mmol/l; female—LPC1 0.195 ± 0.071 vs 0.296 ± 0.044 mmol/l, LPC2 0.037 ± 0.027 vs 0.044 ± 0.014 mmol/l). In addition, female patients with RCC showed lower concentrations of phosphatidylcholines (PC; 1.409 ± 0.268 vs 1.947 ± 0.259 mmol/l). The low phospholipid concentrations normalized for patients in remission. Phospholipid concentrations were found to depend on tumor stage and metastatic spread. The deviations in phospholipid concentrations (LPC1, LPC2, PC) observed may be attributable to systemic effects caused by the tumor as well as changes in enzyme activities. Copyright © 2002 John Wiley & Sons, Ltd.